Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas
- 392 Downloads
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies because of its broad resistance to chemotherapy. Numerous evidence indicates that integrinβ1 is upregulated in some human cancers, and it is correlated with resistance to various therapies. However, the role of integrinβ1 in chemotherapy is not clear in pancreatic cancer. The present study evaluates the potential of integrinβ1 to predict chemoresistance and prognosis in patients and to modulate resistance to gemcitabine in PDAC cells. Primary drug-resistance (DR) cancer cells were isolated, and DR cells from MiaPaCa-2 and AsPC-1 parent cell lines (PCL) were selected. Integrinβ1 expression was determined using immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR) and Western blotting. Changes in drug response after knockdown of integrinβ1 via RNA interference (RNAi) were evaluated using the viability of cancer cells as colon formation, proliferation using Western blot of Ki-67 and apoptosis using cleaved caspase-3 immunofluorescence. qRT-PCR and Western blot also detected variations in the activities of cdc42 and AKT after integrinβ1 suppression. Patient survival and relative factors were assessed using Kaplan-Meier and Cox regression analyses. Integrinβ1 expression was upregulated in PDAC, which was significantly associated with intrinsic and acquired gemcitabine resistance and worse outcomes. The downregulation of integrinβ1 attenuated PDAC chemoresistance, and this attenuation partially correlated with reduced Cdc42 and AKT activity, which are target molecules of integrinβ1 in some human cancers. These findings identified integrinβ1 as a special marker of drug resistance and a serious prognosis, and they furthermore support the use of integrinβ1 as a novel potential therapeutic target to overcome chemotherapy resistance. The results also suggest a possible drug-resistant signalling pathway of integrinβ1 in PDAC.
KeywordsPancreatic ductal adenocarcinoma Integrinβ1 Chemoresistance Survival
The study was supported by Department of Cell Biology, Basic Research Institute, Second Military Medical University (Shanghai, China).
Qingping Cai conceived and designed the experiments. Dejun Yang and Ronglin Ran revised the manuscript and carried out the further experiments. Dejun Yang, Jian Shi, Hongbing Fu, Ziran Wei, Jiapeng Xu and Yu Zhang performed the experiments. Hongbing Fu and Yu Zhang collected the samples and analysed the data. Dejun Yang wrote the paper. All authors are in agreement with the content of the manuscript and this submission. All authors read and approved the final manuscript.
Compliance with ethical standards
Informed consent was obtained from patients, and the study was approved by the Second Military Medical University Research Ethics Committee (Institutional Review Board), Shanghai, China.
Conflicts of interests
- 10.Zhang L, Wu Z, Zhou Q. Epithelial-mesenchymal transition and tumor chemoresistance. Chin J Lung Canc. 2013;16(1):54–7.Google Scholar
- 14.Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, et al. Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2002;2(3):205–16.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006;12(18):5454–63.CrossRefPubMedGoogle Scholar
- 40.Dastpeyman M, Motamed N, Azadmanesh K, Mostafavi E, Kia V, Jahanian-Najafabadi A, et al. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Med Oncol. 2012;29(4):2512–8.CrossRefPubMedGoogle Scholar